Table 2 Main nutrients and dietary recommendations with potential antidepressant effects
Figure 1 Their primary outcome was the rate of recurrent stone events in obese patients with a known history of nephrolithiasis who were maintained on GLP-1As compared to those who were not maintained on GLP-1As
The OASIS 1 trial, published in The Lancet, investigated oral semaglutide at 50mg per day and participants achieved mean weight reductions of around 15%, broadly comparable to the injectable form
The EMPA-KIDNEY trial enrolled a larger proportion of participants without diabetes mellitus and included individuals with lower mean eGFR (37.3 mL/min/1.73 m) and median UACR (329 mg/g) compared to DAPA-CKD
Blockbuster GLP-1 Diabetes and Weight Loss Drugs Fails in Alzheimers Trial Novo Nordisk, the drugmaker behind Wegovy and Ozempic, took a longshot gamble, and lost
The bottom of the plunger head (the flat edge closest to the needle) should align precisely with your target unit marking